Summit Therapeutics (SMMT) Change in Receivables (2017 - 2023)
Summit Therapeutics' (SMMT) quarterly Change in Receivables came in at -$3000.0 in Q3 2023, up 99.76% YoY from -$1501.8 in Q3 2022, and up 50.0% on a QoQ basis from -$6000.0 in Q2 2023.
Summit Therapeutics (SMMT) Change in Receivables (2017 - 2023) Analysis & Trends
Summit Therapeutics (SMMT) has 7 years of Change in Receivables data on file, last reported at -$3000.0 in Q3 2023.
- Quarterly Change in Receivables rose 99.76% year-over-year to -$3000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2024 was -$0.0 (up 100.0% YoY) and the FY2023 annual result came in at -$359000.0, up 63.18% from the prior year.
- Change in Receivables rose to -$3000.0 in Q3 2023, from -$6000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $8.1 million in Q4 2019 to a low of -$3.7 million in Q4 2020.
- A 5-year average of $451387.2 and a median of -$6000.0 in 2023 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2020 — Change in Receivables surged 3290.27% — and 2022, when it sank 499.12%.
- Tracing SMMT's Change in Receivables over 5 years: stood at $8.1 million in 2019, then tumbled by 145.46% to -$3.7 million in 2020, then surged by 74.76% to -$932000.0 in 2021, then jumped by 251.5% to $1.4 million in 2022, then tumbled by 100.21% to -$3000.0 in 2023.
- The last three Change in Receivables figures came in at -$3000.0 (Q3 2023), -$6000.0 (Q2 2023), and -$350000.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -3,000.00 |
| Sep 30, 2023 | -3,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | -350,000.00 |
| Mar 31, 2023 | -350,000.00 |
| Dec 31, 2022 | 1.41 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | -1.23 Mn |
| Sep 30, 2022 | -1.23 Mn |
| Jun 30, 2022 | -705,000.00 |
| Jun 30, 2022 | -705,000.00 |
| Mar 31, 2022 | -455,000.00 |
| Mar 31, 2022 | -455,000.00 |
| Dec 31, 2021 | -932,000.00 |
| Dec 31, 2021 | -932,000.00 |
| Sep 30, 2021 | 1.37 Mn |
| Sep 30, 2021 | 1.37 Mn |
| Jun 30, 2021 | 590,000.00 |
| Jun 30, 2021 | 590,000.00 |